---
layout: post
title: "Mutasi Isocitrate Dehydrogenase 1 dan 2 pada Glioma"
author: "Ni Putu Sriwidyani"
description: "Klasifikasi tumor sistem saraf pusat WHO terakhir didasarkan atas histogenesis tumor dan karakteristik molekuler genetik Perubahan klasifikasi yang paling signifikan te"
categories: jbn
canonical_url: https://jurnal.harianregional.com/jbn/id-66821
comments: true
citation_abstract_html_url: "https://jurnal.harianregional.com/jbn/id-66821"
citation_pdf_url: "https://jurnal.harianregional.com/jbn/full-66821"
tags:

---

## Authors:
Ni Putu Sriwidyani

## Abstract:
"Klasifikasi tumor sistem saraf pusat WHO terakhir didasarkan atas histogenesis tumor dan karakteristik molekuler genetik. Perubahan klasifikasi yang paling signifikan terjadi pada tumor glioma difus yang paling signifikan, yaitu katagori tumor secara garis besar berdasarkan status mutasi isocitrate dehydrogenase (IDH) 1 dan 2. Tulisan ini akan membahas tentang IDH1 dan IDH baik normal maupun mutan, hubungan mutasi IDH1 dan IDH2 dengan prognosis pasien, serta bagaimana penentuan status mutasi IDH1 dan IDH2 dalam diagnosis glioma."

### Keywords
*Keyword Not Available*

### Downloads:
Download data is not yet available.

{% include adsense.html %}
## References
- Louis DN, Perry A, Reifenberger G, dkk. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803-20.
- 2.	Lee SC. Diffuse gliomas for nonneuropathologists: The new integrated molecular diagnostics. Arch Pathol Lab Med. 2018;142:804-14.
- 3.	Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: Mechanisms, models, and clinical opportunities. Cancer Discov. 2013;3:730-41.
- 4.	Maus A, Peters GJ. Glutamate and α-ketoglutarate: key players in glioma metabolism. Amino Acids. 2017;49:21-32.
- 5.	Tommasini-Ghelfi S, Murnan K, Kouri FM, dkk. Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease. Sci Adv.2019;5:eaaw4543.
- 6.	Turkalp Z, Karamchandani J, Das S. IDH mutation in glioma: New insights and promises for the future. JAMA Neurol. 2014;71:1319-25.
- 7.	Monga V, Jones K, Chang S. Clinical Relevance Of Molecular Markers In Gliomas. Rev Médica Clínica Las Condes. 2017;28:343-51.
- 8.	Yan H, Parsons DW, Jin G, dkk. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-73.
- 9.	Huang J, Yu J, Tu L, dkk. Isocitrate dehydrogenase mutations in glioma: From basic discovery to therapeutics development. Front Oncol. 2019;9:506.
- 10.	Olar A, Wani KM, Alfaro-Munoz KD, dkk. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas. Acta Neuropathol.2015; 129:585-596
- 11.	Komori T. The 2016 WHO classification of tumours of the central nervous system: The major points of revision. Neurol Med Chir (Tokyo). 2017;57:301-11.

### PDF:

{% include adsense1.html %}

<https://jurnal.harianregional.com/jbn/full-66821>

{% include adsense2.html %}

### Published
2020-12-30

### How To Cite
SRIWIDYANI, Ni Putu.  Mutasi Isocitrate Dehydrogenase 1 dan 2 pada Glioma.JBN (Jurnal Bedah Nasional), [S.l.], v. 5, n. 1, p. 26-30, dec. 2020. ISSN 2548-981X. Available at: <https://jurnal.harianregional.com/jbn/id-66821>. Date accessed: {{ site.time | date: "%d %b. %Y" }}. doi:https://doi.org/10.24843/JBN.2021.v05.i01.p05.

## Citation Format
ABNT, APA, BibTeX, CBE, EndNote - EndNote format (Macintosh & Windows), MLA, ProCite - RIS format (Macintosh & Windows), RefWorks, Reference Manager - RIS format (Windows only), Turabian

### Issue
Vol 5 No 1 (2021): JBN (Jurnal Bedah Nasional)

### Section 
**Articles**

### Copyright 
{% include inarticle.html %}
<a href="http://creativecommons.org/licenses/by/4.0/" rel="license"><img src="https://i.creativecommons.org/l/by/4.0/88x31.png" alt="Creative Commons License" /></a>
This work is licensed under a <a href="http://creativecommons.org/licenses/by/4.0/" rel="nofollow">Creative Commons Attribution 4.0 International License</a>

{% include multiplex.html %}
